Aspirin for Preventing the Recurrence of Venous Thromboembolism

Becattini, Cecilia; Agnelli, Giancarlo; Schenone, Alessandro; Eichinger, Sabine; Bucherini, Eugenio; Silingardi, Mauro; Bianchi, Marina; Moia, Marco; Ageno, Walter; Vandelli, Maria Rita; Grandone, Elvira; Prandoni, Paolo
May 2012
New England Journal of Medicine;5/24/2012, Vol. 366 Issue 21, p1959
Academic Journal
Background: About 20% of patients with unprovoked venous thromboembolism have a recurrence within 2 years after the withdrawal of oral anticoagulant therapy. Extending anticoagulation prevents recurrences but is associated with increased bleeding. The benefit of aspirin for the prevention of recurrent venous thromboembolism is unknown. Methods: In this multicenter, investigator-initiated, double-blind study, patients with first-ever unprovoked venous thromboembolism who had completed 6 to 18 months of oral anticoagulant treatment were randomly assigned to aspirin, 100 mg daily, or placebo for 2 years, with the option of extending the study treatment. The primary efficacy outcome was recurrence of venous thromboembolism, and major bleeding was the primary safety outcome. Results: Venous thromboembolism recurred in 28 of the 205 patients who received aspirin and in 43 of the 197 patients who received placebo (6.6% vs. 11.2% per year; hazard ratio, 0.58; 95% confidence interval [CI], 0.36 to 0.93) (median study period, 24.6 months). During a median treatment period of 23.9 months, 23 patients taking aspirin and 39 taking placebo had a recurrence (5.9% vs. 11.0% per year; hazard ratio, 0.55; 95% CI, 0.33 to 0.92). One patient in each treatment group had a major bleeding episode. Adverse events were similar in the two groups. Conclusions: Aspirin reduced the risk of recurrence when given to patients with unprovoked venous thromboembolism who had discontinued anticoagulant treatment, with no apparent increase in the risk of major bleeding. (Funded by the University of Perugia and others; WARFASA ClinicalTrials.gov number, NCT00222677.)


Related Articles

  • Aspirin and the Prevention of Venous Thromboembolism. Becker, Richard C. // New England Journal of Medicine;5/24/2012, Vol. 366 Issue 21, p2028 

    The article discusses the effectiveness of aspirin in reducing the risk of venous thromboembolism. In 2002, a study found that an antiplatelet therapy led to a 39% reduction in the risk of venous thromboembolism in high-risk patients. It notes that the adverse-event profile of aspirin is...

  • Is aspirin plus dipyridamole as effective as clopidogrel for preventing recurrent stroke?  // Journal of Family Practice;Dec2008, Vol. 57 Issue 12, p781 

    The article provides facts on the idea that taking aspirin along with dipyridamole would be effective as taking clopidrogel for preventing recurrent stroke in the U.S. It notes that the combination of asprin and dipyridamole are similarly effective to clopidrogel. However, it connotes that...

  • Clopidogrel + aspirin in atrial fibrillation. Kuritzky, Louis // Clinical Oncology Alert;Aug2009 Supplement, p15 

    The article discusses research which investigated the effect of adding clopidogrel (CPG) to aspirin (ASA) on patients with atrial fibrillation (FIB). It references a study which appeared in the "New England Journal of Medicine." The efficacy of CPG with ASA therapy was evaluated among patients...

  • Emerging antithrombotic drugs: A review. Sikka, P.; Bindra, V. K. // Annals of Tropical Medicine & Public Health;Jul-Dec2011, Vol. 4 Issue 2, p138 

    Thromboembolic disorders are one of the disorders for which the researchers are still in search for a safe and efficient drug. Despite the widespread use of antithrombotic drugs for the prevention and treatment of arterial and venous thrombosis, thromboembolic diseases continue to be a major...

  • Despite hemorrhage risk, advanced age need not preclude warfarin use.  // Geriatrics;Dec95, Vol. 50 Issue 12, p61 

    Presents an abstract of the study `Bleeding and thromboembolism during anticoagulant therapy: A population-based study in Rochester, Minnesota,' by M.J. Gitter, T.M. Jaeger et al, published in a 1995 issue of the periodical `Mayo Clinic Proceedings.'

  • Dabigatran etexilate: Thromboembolism: case report.  // Reactions Weekly;Dec2013, Issue 1481, p15 

    The article presents a case study of a 57-year-old man who experienced thromboembolism during his treatment with dabigatran etexilate.

  • Aspirin.  // Reactions Weekly;6/13/2009, Issue 1256, p9 

    The article describes the case of a 67-year-old man with unrecognised platelet dysfunction who experienced spontaneous haemorrhages during antiplatelet drug therapy with aspirin. The patient's medical history and treatment regimen are discussed. An overview of the findings from diagnostic tests...

  • Ticlopidine and Clopidogrel: Do They Have Direct Vascular Effects? Wehrmacher, William H.; Messmore, Harry L.; Bick, Rodger L.; Fareed, Jawed // Clinical & Applied Thrombosis/Hemostasis;Oct1997, Vol. 3 Issue 4, p225 

    Highlights various research on antiplatelet drugs, ticlopidine and clopidogrel. Efficacy of ticlopidine; Factor which influences the beneficial effects of the agents; Side effect of the drugs.

  • Apixaban, sodium picosulfate, and regorafenib. Hussar, Daniel A.; Koval, Jonathan M. // Journal of the American Pharmacists Association: JAPhA;Mar/Apr2013, Vol. 53 Issue 2, p217 

    The article focuses on three anticoagulants namely apixaban, sodium picosulfate and regorafenib. It reports the approval of dabigatran in 2010, rivaroxaban in 2011 and apixaban in December 2012. It discusses the efficacy, administration and adverse effects of apixaban, sodium picosulfate and...


Read the Article


Sign out of this library

Other Topics